Advanced Filters
noise

Tokyo and Other Japanese City, Japan Clinical Trials

A listing of Tokyo and Other Japanese City, Japan clinical trials actively recruiting patients volunteers.

Found 61,726 clinical trials
M Michelle Chin, MS, MPH

Behavioral Assessment and Treatment of Problem Behavior in Children With Cornelia de Lange Syndrome

The goals of this clinical trial are to identify factors associated with the development of problem behavior in Cornelia de Lange syndrome (CdLS) and to develop an effective behavioral assessment and treatment model for problem behavior in children with CdLS. The hypotheses are as follows: Based on pilot data, the …

3 - 15 years of age All Phase N/A
C Colin Burnett

Home Transcutaneous Electrical Acustimulation (TEA)

This study will assess the efficacy of two active treatments with TEA and a chemical neuromodulator (escitalopram aka Lexapro) versus a sham comparator or control group on abdominal pain.

18 years of age All Phase 2/3
M Marissa Podell

A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis

The purpose of this pilot study to examine the feasibility and acceptability of paricalcitol in adults with Chronic Pancreatitis (CP).

18 - 75 years of age All Phase N/A
K Kameron Simmons

Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder

This is a randomized, double-blind, placebo-controlled phase 2b pilot clinical trial to determine whether non-ergoline D3/D2/D1 dopamine (DA) receptor agonist rotigotine (RTG), in combination with treatment as usual, including individual or group behavioral therapy can a) reduce cocaine use and also b) increase brain activity in frontocortical areas of the …

18 - 55 years of age All Phase 2
J Justin Watts, MD

Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

This is an open-label Phase 1b study of NEROFE following a traditional 3+3 design to assess safety and to determine the Recommended Phase 2 Dose (RP2D) of NEROFE in patients with MDS or AML. IV NEROFE will be administered three times per week on alternate days. The exact dosage will …

18 years of age All Phase 1
W Wei Qiu, MD

RC18 in Patients With Relapsing Remitting Multiple Sclerosis:a Phase II Trial

To observe the safety and effectivity of a Recombinant Human B Lymphocyte Stimulator Receptor : Immunoglobulin G( IgG ) Fc Fusion Protein for injection (RC18) in patients with relapsing remitting multiple sclerosis, analyze the dose-response relationship and provide a dose basis for follow-up clinical trials.

18 - 55 years of age All Phase 2

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

First-in-human, open-label, dose-finding and dose-expansion study of UCART20x22 administered intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to evaluate the safety and clinical activity of UCART20x22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).

18 - 80 years of age All Phase 1/2
M Megan E Shott, BS

Therapeutic Ketogenic Diet in Anorexia Nervosa

This study will investigate the effects of therapeutic ketogenic diet (TKD) on eating behavior including drive to restrict, body dissatisfaction, mood and anxiety in individuals with anorexia nervosa who have been weight normalized (body mass index of 17.5 or greater) but continue to struggle with eating disorder behaviors including a …

18 - 45 years of age All Phase N/A
O Olga H Meléndez-Fernández, BS

Effects of Blocking Blue Light at Night Post CABG, AVR, MVR, CABG AVR, CABG MVR, or SAH

Purpose The purpose of this study is to determine whether filtering out blue light at nighttime reduces post-surgical inflammation and/or moderates cognitive decline and mood and sleep alterations in patients undergoing elective CABG, AVR, MVR, CABG AVR, CABG MVR, or SAH surgery. If manipulating nighttime light in hospital rooms improves …

45 - 75 years of age All Phase N/A
T Tara Wright, PhD, MS

KIOS Mobile App Evaluation

Evaluation of a mobile medical app (KIOS) vs. treatment as usual for the treatment of opioid use disorder (OUD).

18 years of age All Phase N/A

Simplify language using AI